Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 10/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 9/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.61 |
| ▸ | NPC1 | O15118 | 8/20 | 0.61 |
| ▸ | RAB9A | P51151 | 8/20 | 0.61 |
| ▸ | HPGD | P15428 | 4/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.61 |
| ▸ | TP53 | P04637 | 2/20 | 0.61 |
| ▸ | GAA | P10253 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | PKM | P14618 | 4/20 | 0.54 |
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.54 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.54 |
| ▸ | RELA | Q04206 | 1/20 | 0.54 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31063832 | 1.00 | HDAC6 (0.70) | HDAC6KDM4ESMN1; SMN2ALDH1A1NPC1 | |
| SCHEMBL31027899 | 0.88 | HDAC6 (0.74) | HDAC6KDM4ESMN1; SMN2ALDH1A1NPC1 | |
| SCHEMBL22452438 | 0.88 | HDAC6 (0.74) | HDAC6KDM4ESMN1; SMN2ALDH1A1NPC1 | |
| SCHEMBL21705326 | 0.85 | NPBWR1 (0.67) | HDAC6KDM4ESMN1; SMN2ALDH1A1NPC1 | |
| SCHEMBL30011485 | 0.85 | NPBWR1 (0.67) | HDAC6KDM4ESMN1; SMN2ALDH1A1NPC1 | |
| SCHEMBL21087571 | 0.84 | NPC1 (0.67) | HDAC6KDM4ESMN1; SMN2ALDH1A1NPC1 | |
| SCHEMBL20806658 | 0.84 | NPC1 (0.52) | HDAC6KDM4ESMN1; SMN2ALDH1A1NPC1 | |
| SCHEMBL3417301 | 0.84 | NPC1 (0.78) | KDM4ESMN1; SMN2ALDH1A1NPC1RAB9A | |
| SCHEMBL22955865 | 0.83 | KDM4E (0.50) | HDAC6KDM4ESMN1; SMN2ALDH1A1NPC1 | |
| SCHEMBL34460121 | 0.83 | MEN1 (0.57) | HDAC6KDM4ESMN1; SMN2ALDH1A1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024118936-A1 | 2-ARYLBENZIMIDAZOLE COMPOUNDS FOR THE TREATMENT OF HEMOGLOBINOPATHIES | TRANQUIS THERAPEUTICS, INC. (US) | 2024-06-06 | — | — | WO | claimed |
| WO-2024118936-A1 | 2-ARYLBENZIMIDAZOLE COMPOUNDS FOR THE TREATMENT OF HEMOGLOBINOPATHIES | TRANQUIS THERAPEUTICS, INC. (US) | 2024-06-06 | — | — | WO | disclosed |
| US-20210300877-A1 | 2-ARYLBENZIMIDAZOLES AS PPARGC1A ACTIVATORS FOR TREATING NEURODEGENERATIVE DISEASES | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2021-09-30 | — | — | US | disclosed |
| US-11111217-B2 | 2-arylbenzimidazoles as Ppargc1a activators for treating neurodegenerative diseases | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2021-09-07 | — | — | US | disclosed |
| US-20210061769-A1 | 2-ARYLBENZIMIDAZOLES AS PPARGC1A ACTIVATORS FOR TREATING NEURODEGENERATIVE DISEASES | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2021-03-04 | — | — | US | disclosed |
| US-10851066-B2 | 2-arylbenzimidazoles as PPARGC1A activators for treating neurodegenerative diseases | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2020-12-01 | — | — | US | disclosed |
| US-10851066-B2 | 2-arylbenzimidazoles as PPARGC1A activators for treating neurodegenerative diseases | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2020-12-01 | — | — | US | disclosed |
| US-20200299244-A1 | 2-ARYLBENZIMIDAZOLES AS PPARGC1A ACTIVATORS FOR TREATING NEURODEGENERATIVE DISEASES | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2020-09-24 | — | — | US | disclosed |
| US-10442788-B2 | Hepatitis B antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2019-10-15 | — | — | US | disclosed |
| US-10280175-B2 | Hepatitis B antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2019-05-07 | — | — | US | disclosed |
| US-20170217974-A1 | HEPATITIS B ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2017-08-03 | — | — | US | disclosed |
| US-20070032475-A1 | Novel compounds useful for bradykinin B1 receptor antagonism | ELAN PHARMACEUTICALS, INC. | 2007-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200299244-A1 | 2-ARYLBENZIMIDAZOLES AS PPARGC1A ACTIVATORS FOR TREATING NEURODEGENERATIVE DISEASES | PPARG, PPARA, PPARD | HDAC6 101/4885KDM4E 2310/4885SMN1; SMN2 593/4885 |
| US-20210300877-A1 | 2-ARYLBENZIMIDAZOLES AS PPARGC1A ACTIVATORS FOR TREATING NEURODEGENERATIVE DISEASES | PPARG, PPARA, PPARD | HDAC6 91/4885KDM4E 2901/4885SMN1; SMN2 39/4885 |
| US-20210061769-A1 | 2-ARYLBENZIMIDAZOLES AS PPARGC1A ACTIVATORS FOR TREATING NEURODEGENERATIVE DISEASES | PPARG, PPARA, PPARD | HDAC6 107/4885KDM4E 2302/4885SMN1; SMN2 472/4885 |
| US-11111217-B2 | 2-arylbenzimidazoles as Ppargc1a activators for treating neurodegenerative diseases | PPARG, PPARA, PPARD | HDAC6 107/4885KDM4E 2302/4885SMN1; SMN2 472/4885 |
| US-20170217974-A1 | HEPATITIS B ANTIVIRAL AGENTS | HAVCR2, ZC3HAV1, SLC10A1 | HDAC6 1114/4885KDM4E 1172/4885SMN1; SMN2 4809/4885 |
| US-10851066-B2 | 2-arylbenzimidazoles as PPARGC1A activators for treating neurodegenerative diseases | PPARG, PPARA, PPARD | HDAC6 101/4885KDM4E 2310/4885SMN1; SMN2 593/4885 |
| US-10442788-B2 | Hepatitis B antiviral agents | ZC3HAV1, ZC3HAV1L, HAVCR2 | HDAC6 1930/4885KDM4E 1390/4885SMN1; SMN2 4775/4885 |
| US-10280175-B2 | Hepatitis B antiviral agents | ZC3HAV1, HAVCR2, SLC10A1 | HDAC6 1215/4885KDM4E 1439/4885SMN1; SMN2 4817/4885 |
| US-20070032475-A1 | Novel compounds useful for bradykinin B1 receptor antagonism | BDKRB1, BDKRB2, NPBWR1 | HDAC6 4325/4885KDM4E 4606/4885SMN1; SMN2 2731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.